Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM
Andrzej Jakubowiak,Massimo Offidani,Brigitte Pégourie,Javier De La Rubia,Laurent Garderet,Kamel Laribi,Alberto Bosi,Roberto Marasca,Jacob Laubach,Ann Mohrbacher,Angelo Michele Carella,Anil K. Singhal,L.Claire Tsao,Mark Lynch,Eric Bleickardt,Ying-Ming Jou,Michael Robbins,Antonio Palumbo Blood(2016)
AI 理解论文
溯源树
样例